Hoping to land on its feet after a tough year, Stada is nearly ready to announce drug industry veteran Claudio Albrecht as its next CEO. The news, coming from Bloomberg’s sources, follows more than a year of developments that were disappointing, dramatic and just plain strange.
After its €5.3 billion ($6.3 billion) buyout from investment firms Bain and Cinven fell short back in July, the drugmaker brought in former Boehringer Ingelheim executive Engelbert Coster Tjeenk Willink to serve as interim CEO. Bernhard Düttmann, a financial veteran, was named interim CFO. Bain and Cinven have since sweetened their offer and the companies are now working to win enough shareholder support to close the deal.
Now, in a move that will mark its fourth CEO in a little over a year, the drugmaker is nearing an announcement for Albrecht as its next leader, according to Bloomberg. Albrecht is a former CEO of two European generic firms, the news service reports.
Stada’s dramatic year has featured the exit of longtime CEO Hartmut Retzlaff last June due to a “serious, long-term illness.” When his successor Mattias Wiedenfels took the helm, he quickly stripped Retzlaff’s son of some duties and fired advisors.
The company has meanwhile dealt with with activist investor attention from Active Ownership Capital, which pushed to replace board members with its own candidates. After significant drama, the company nearly finished a deal to sell itself to Bain Capital and Cinven this year, but couldn’t win enough shareholder support.
As for the weird, Wiedenfels discovered he was the target of a spying operation as deal talks heated up, according to a report from Manager Magazin. According to that publication, the former helmsman found a recording device in his car and received photographs of himself in personal or private business situations.
By Eric Sagonowsky
Source: Fierce Pharma
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
